SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (220)10/9/2018 12:53:29 PM
From: semi_infinite   Read Replies (3) | Respond to of 294
 
Perhaps it is a leak of the Celgene cd47 trial termination. FTSV and SURF getting hammered too.



To: Biomaven who wrote (220)10/9/2018 4:07:07 PM
From: semi_infinite   Respond to of 294
 
Assuming that it was the CELG news leak at clinics that precipitated the sell off, I bought back shares that I sold when the stock broke $5. I still haven't bought back all the shares yet but will do so over the next few days.



To: Biomaven who wrote (220)11/13/2018 1:10:04 PM
From: Bladerunner17  Respond to of 294
 
Peter,

Any new thoughts on TRIL, after looking at the abstracts? Any new thoughts on the price drop?

Bladerunner


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News